About

About OBI Pharma, Inc. OBI Pharma, Inc., is a Taiwan biopharmaceutical company publicly-listed on the Taipei Exchange (TPex ticker: 4174). OBI’s mission is to develop and license novel therapeutic agents for unmet medical needs of cancer patients. OBI holds proprietary ADC platform technologies and has a novel oncology portfolio: ADC platform technologies - GlycOBI™ - ThiOBI™ Novel cancer therapeutics - Adagloxad Simolenin (formerly OBI-822; Globo H cancer vaccine) - OBI-833 (Globo H cancer vaccine) - OBI-3424 (small-molecule prodrug targeting AKR1C3 enzyme) - OBI-992 (TROP2 ADC, Cys-conjugation platform) - OBI-902 (TROP2 ADC, GlycOBI platform) - OBI-904 (Nectin4 ADC, GlycOBI platform) About OBI Pharma, Inc. OBI Pharma, Inc., is a Taiwan biopharmaceutical company publicly-listed on the Taipei Exchange (TPex ticker: 4174). OBI’s mission is to develop and license novel therapeutic agents for unmet medical needs of cancer patients. OBI holds proprietary ADC platform technologies and has a novel oncology portfolio: ADC platform technologies - GlycOBI™ - ThiOBI™ Novel cancer therapeutics - Adagloxad Simolenin (formerly OBI-822; Globo H cancer vaccine) - OBI-833 (Globo H cancer vaccine) - OBI-3424 (small-molecule prodrug targeting AKR1C3 enzyme) - OBI-992 (TROP2 ADC, Cys-conjugation platform) - OBI-902 (TROP2 ADC, GlycOBI platform) - OBI-904 (Nectin4 ADC, GlycOBI platform) OBI Pharma strategically advances next-generation antibody-drug conjugates (ADCs) targeting major cancer indications, including TROP2, Nectin4, HER2, and dual-antigen targets. Its pipeline is supported by a comprehensive suite of proprietary ADC enabling technologies, such as GlycOBI®, GlycOBI DUO®, EndoSymeOBI®, ThiOBI®, and HYPrOBI®. These platforms combine precise glycan modification with innovative linker design to address key challenges in ADC development and manufacturing. They enable stable, scalable production, precise control of drug-to-antibody ratio (DAR), and highly uniform products with improved safety and efficacy. Through these innovations, OBI Pharma is positioned to deliver transformative ADC therapies globally—advancing first- and best-in-class cancer treatments from Taiwan to address critical unmet medical needs.